drugset / Trial / NCT03745144

Effects of Cladribine Tablets on the PK of Microgynon®

NCT03745144

Phase 1 Completed 28 enrolled Merck KGaA, Darmstadt, Germany
RandomizedCrossoverDouble-blindOther

Summary

The purpose of this study was to investigate the potential effects of cladribine on the pharmacokinetics (PK) of monophasic oral contraceptive microgynon® by assessment of its constituents, ethinyl estradiol (EE) and levonorgestrel (LNG).

Timeline

Start
2019-01-17
Primary completion
2022-09-02
Completion
2022-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Cladribine Small molecule 10 mg
Subject Cladribine Small molecule 20 mg
Subject Microgynon Unknown Oral